Evidence map›Paper›PMID 37213477›Full record

ArticleInternational journal of general medicine2023

Lectin Complement Pathway Activation is Associated with Massive Proteinuria in PLA2R-Positive Membranous Nephropathy: A Retrospective Study.

Jiayi Li, Jiao Zhang, Xu Wang, Xumin Zheng, Hongmei Gao, Shimin Jiang, Wenge Li

Open access · goldAbstract read
In one paragraph

Article in International journal of general medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Hyperlipidemia in membranous nephropathy.Clinical kidney journal · 2026
    Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jiayi LiDepartment of Nephrology, Peking University China-Japan Friendship School of Clinical Medicine, Beijing, People's Republic of China.
Jiao ZhangDepartment of Nephrology, China-Japan Friendship Hospital, Beijing, People's Republic of China.
Xu WangDepartment of Nephrology, China-Japan Friendship Hospital, Beijing, People's Republic of China.
Xumin ZhengDepartment of Nephrology, China-Japan Friendship Hospital, Beijing, People's Republic of China.
Hongmei GaoDepartment of Nephrology, China-Japan Friendship Hospital, Beijing, People's Republic of China.
Shimin JiangDepartment of Nephrology, China-Japan Friendship Hospital, Beijing, People's Republic of China.
Wenge LiDepartment of Nephrology, Peking University China-Japan Friendship School of Clinical Medicine, Beijing, People's Republic of China.
China-Japan Friendship Hospital · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Complement activation is highly involved in membranous nephropathy. Identifying the mechanism of the complement activation pathway carries crucial therapeutic implications yet remains controversial. This study explored lectin complement pathway activation in PLA2R-associated membranous nephropathy (MN). Methods: One hundred and seventy-six patients with biopsy-proven PLA2R-associated MN were enrolled in the retrospective study and divided into the remission group (24-hour urine protein <0.75g and serum albumin >35 g/L) and the nephrotic syndrome group. The clinical manifestation and C3, C4d, C1q, MBL, and B factor in renal biopsy tissues and C3, C4, and immunoglobulins in serum were evaluated. Results: Deposition of glomerular C3, C4d, and mannose-binding lectin (MBL) was significantly higher in the activated state than in the remission state in PLA2R-associated MN. MBL deposition was the risk factor for no remission. During follow-up, the persistent non-remission patients have significantly lower serum C3 levels. Conclusion: Activation of the lectin complement pathway in PLA2R-associated MN may contribute to proteinuria progression and disease activity.

Indexed as

anti-PLA2R antibodycomplementlectin pathwaymembranous nephropathy

Identifiers

PMID37213477
PMCPMC10195059
OpenAlexW4376959706

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.